PMID- 19675076
OWN - NLM
STAT- MEDLINE
DCOM- 20100216
LR  - 20210816
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
VI  - 16
IP  - 4
DP  - 2009 Dec
TI  - Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: 
      determination by kinetic PCR in formalin-fixed paraffin-embedded tissue.
PG  - 1229-39
LID - 10.1677/ERC-08-0338 [doi]
AB  - Epidemiological and cell culture studies indicate that ovarian carcinoma growth 
      is dependent on estrogen stimulation. However, possibly due to the lack of a 
      reliable biomarker that helps to select patients according to prognostically 
      relevant estrogen receptor (ER) levels, clinical trials using anti-estrogenic 
      therapeutics in ovarian carcinoma have had inconsistent results. Therefore, we 
      tested if ER expression analysis by a quantitative method might be useful in this 
      regard in formalin-fixed paraffin-embedded (FFPE) tissue. In a study group of 114 
      primary ovarian carcinomas expression of estrogen receptor 1 (ESR1) mRNA was 
      analyzed using a new method for RNA extraction from FFPE tissue that is based on 
      magnetic beads, followed by kinetic PCR. The prognostic impact of ESR1 mRNA 
      expression was investigated and compared to ERalpha protein expression as 
      determined by immunohistochemistry. In univariate survival analysis the 
      expression level of ESR1 mRNA was a significant positive prognostic factor for 
      patient survival (hazard ratio (HR) 0.230 (confidence interval (CI) 0.102-0.516), 
      P=0.002). ERalpha protein expression was correlated to ESR1 mRNA expression 
      (P=0.0001); however, ERalpha protein expression did not provide statistically 
      significant prognostic information. In multivariate analysis, ESR1 mRNA 
      expression emerged as a prognostic factor, independent of stage, grade, residual 
      tumor mass, age, and ERalpha protein expression (HR 0.227 (CI 0.078-0.656), 
      P=0.006). Our results indicate that the determination of ESR1 levels by kinetic 
      PCR may be superior to immunohistochemical methods in assessment of biologically 
      relevant levels of ER expression in ovarian carcinoma, and is feasible in 
      routinely used FFPE tissue.
FAU - Darb-Esfahani, Silvia
AU  - Darb-Esfahani S
AD  - Institute of Pathology, Charite Universitatsmedizin Berlin, Berlin, Germany. 
      silvia.darb-esfahani@charite.de
FAU - Wirtz, Ralph M
AU  - Wirtz RM
FAU - Sinn, Bruno V
AU  - Sinn BV
FAU - Budczies, Jan
AU  - Budczies J
FAU - Noske, Aurelia
AU  - Noske A
FAU - Weichert, Wilko
AU  - Weichert W
FAU - Faggad, Areeg
AU  - Faggad A
FAU - Scharff, Susanne
AU  - Scharff S
FAU - Sehouli, Jalid
AU  - Sehouli J
FAU - Oskay-Ozcelik, Guelten
AU  - Oskay-Ozcelik G
FAU - Zamagni, Claudio
AU  - Zamagni C
FAU - De Iaco, Pierandrea
AU  - De Iaco P
FAU - Martoni, Andrea
AU  - Martoni A
FAU - Dietel, Manfred
AU  - Dietel M
FAU - Denkert, Carsten
AU  - Denkert C
LA  - eng
PT  - Journal Article
DEP - 20090812
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ESR1 protein, human)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Adenocarcinoma, Clear Cell/genetics/metabolism/secondary
MH  - Adenocarcinoma, Mucinous/genetics/metabolism/secondary
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Carcinoma, Transitional Cell/genetics/metabolism/secondary
MH  - Cystadenocarcinoma, Serous/genetics/metabolism/secondary
MH  - Endometrial Neoplasms/genetics/metabolism/secondary
MH  - Estrogen Receptor alpha/*genetics/metabolism
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Middle Aged
MH  - Ovarian Neoplasms/*genetics/metabolism/pathology
MH  - Paraffin Embedding
MH  - Prognosis
MH  - RNA, Messenger/*genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2009/08/14 09:00
MHDA- 2010/02/17 06:00
CRDT- 2009/08/14 09:00
PHST- 2009/08/14 09:00 [entrez]
PHST- 2009/08/14 09:00 [pubmed]
PHST- 2010/02/17 06:00 [medline]
AID - ERC-08-0338 [pii]
AID - 10.1677/ERC-08-0338 [doi]
PST - ppublish
SO  - Endocr Relat Cancer. 2009 Dec;16(4):1229-39. doi: 10.1677/ERC-08-0338. Epub 2009 
      Aug 12.